COMMUNIQUÉS West-GlobeNewswire

Vincerx Pharma Announces Termination of Reverse Merger Term Sheet and Evaluation of Strategic Alternatives

28/02/2025 - 22:05

SAN MATEO, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced that the previously signed binding Term Sheet between Vincerx, Oqory, Inc., and Vivasor, Inc. for a reverse merger [...]

4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

28/02/2025 - 22:05

Presented positive interim data through 52 weeks and beyond for 4D-150 in wet AMD from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse patient populations and continued [...]

Alignment Healthcare Reports Fourth Quarter and Full-Year 2024 Results; Provides Full-Year 2025 Financial Guidance

27/02/2025 - 22:01

Reports 189,100 health plan members as of Dec. 31, 2024, up 58.6% year-over-year, beating year-end expectations Achieves first full year of positive adjusted EBITDA as a public company, driven by operating leverage and [...]

WW International, Inc. Announces Fourth Quarter and Full Year 2024 Results

27/02/2025 - 22:01

Fourth Quarter 2024 Financial Highlights Total End of Period Subscribers of 3.3 million, including 92 thousand End of Period Clinical Subscribers Revenues of $184.4 million; Subscription Revenues down 7.3% vs. prior [...]

Xenon Reports Fourth Quarter & Full Year 2024 Financial Results and Business Update

27/02/2025 - 22:01

– Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch – First of three planned Phase 3 azetukalner MDD studies underway, with second [...]

Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

27/02/2025 - 22:01

Enrollment ongoing in Phase 3 barzolvolimab CSU studies; Phase 3 program in CIndU under development Phase 2 barzolvolimab EOE study fully accrued; Phase 2 study initiated in atopic dermatitis; enrollment ongoing in [...]

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Fourth Quarter and Full Year 2024

27/02/2025 - 22:01

Significant Demand for Amtagvi® (Lifileucel) Continues with Total Product Revenue of $73.7M in 4Q24 and $164.1M in FY24, Achieving Upper End of FY24 Guidance Range of $160M-$165M Reaffirming FY25 Total Product Revenue [...]

Standard BioTools to Participate in Upcoming Investor Conferences

27/02/2025 - 22:01

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that company management will participate in the following investor conferences: TD Cowen’s 45th Annual [...]

Progyny, Inc. Announces Fourth Quarter 2024 Results

27/02/2025 - 22:01

Reports Quarterly Revenue of $298.4 Million, Reflecting 10.6% Growth Generated $52.2 Million of Quarterly Operating Cash Flow Issues Financial Guidance for 2025, Reflecting Tenth Consecutive Year of Revenue Growth NEW [...]

NurExone Biologic to Present at MIXiii 2025; Professor Michael Belkin, Head of NurExone Ophthalmology Project, to Receive Lifetime Achievement Award

27/02/2025 - 22:03

TORONTO and HAIFA, Israel, Feb. 27, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is pleased to announce that it has been selected to present at [...]

ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2024

27/02/2025 - 22:03

Reshaping its Board of Directors at the upcoming Shareholders’ meeting with the aim of enhancing U.S. outreach Preparations for PORTICO-2 Phase III trial with vafidemstat in agitation/aggression in Borderline [...]

Structure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Highlights

27/02/2025 - 22:05

Aleniglipron (GSBR-1290) ACCESS and ACCESS II studies fully enrolled; topline data from both studies anticipated by year-end 2025 Oral small molecule amylin receptor agonist (ACCG-2671) Investigational New Drug (IND)- [...]

Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress

27/02/2025 - 22:05

Topline data readouts from multiple Phase 2 studies expected throughout 2025 VTX2735 in patients with recurrent pericarditis in H2 VTX3232 in participants with obesity and cardiometabolic risk factors in H2 VTX3232 [...]

Cytek Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook

27/02/2025 - 22:05

FREMONT, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cytek ® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the fourth [...]

Seer Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Outlook

27/02/2025 - 22:05

Validated technology with exceptional growth of customer publications and enhanced access to the Proteograph Product Suite with growing demand for Seer Technology Access Center (STAC) REDWOOD CITY, Calif., Feb. 27, 2025 [...]

Pacira BioSciences Reports Fourth Quarter and Full-Year 2024 Financial Results

27/02/2025 - 22:05

— Record revenues of $701 million in 2024 — — Full-year GAAP net loss of $100 million and adjusted EBITDA of $224 million — — Conference call today at 4:30 p.m. ET — PARSIPPANY, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- [...]

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

27/02/2025 - 22:05

Commercial Preparations On-Track Ahead of September 25, 2025 PDUFA Date Including Regulatory Review Process, Organizational Build, and Key Stakeholder Engagement Efforts Expecting to Initiate Four Late-Stage Trials and [...]

Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

27/02/2025 - 22:05

REDWOOD CITY, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a [...]

89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

27/02/2025 - 22:05

– ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic dysfunction-associated steatohepatitis (MASH) continue to advance with topline [...]